The chemokine receptor CXCR4 (a receptor for the Cys-X-Cys class of chemokines) is a CD4-associated coreceptor for T-cell-tropic strains of human immunodeficiency virus 1 (HIV-1) and represents a target for antiviral therapy. Infection by T-tropic HIV-1 can be blocked by stromal-cell-derived factor-1 (SDF-1), the natural ligand of CXCR4. The broad variety of cells expressing CXCR4 and the perturbations observed in mice deficient for SDF-1 suggest that antiviral compounds antagonizing the signalling activity of CXCR4 might have severe side effects in vivo. Compounds that interfere selectively with HIV entry and not with SDF-1 signalling would therefore be useful.
Background
Expression of the chemokine receptors CCR5 (a receptor for the Cys-Cys class of chemokines) or CXCR4 (a receptor for the Cys-X-Cys class of chemokines) in CD4 + cells allows these cells to be infected by the human immunodeficiency virus 1 (HIV-1). CCR5 and CXCR4 can interact with the HIV-1 envelope protein gp120 in the presence of CD4, suggesting that they behave as CD4-associated coreceptors for HIV-1 (reviewed in [1] ). A similar coreceptor activity has been reported for several other G-protein-coupled receptors [2] , but it is not clear whether these receptors can be used by HIV-1 in vivo. Whereas CCR5 is used as a coreceptor by most primary HIV-1 strains, in particular macrophage (M)-tropic strains, CXCR4 is used by the T-tropic subset of primary HIV-1 strains, which replicate in CD4 + lymphocytes and in T-cell lines [1] . T-tropic strains are generally isolated at late stages of HIV-1 infection, and their emergence has been proposed to play a role in the progression towards AIDS [3, 4] . A therapeutic benefit could therefore be expected from compounds inhibiting the coreceptor function of CXCR4. Also, because only a few mutations in gp120 are required for HIV-1 to switch from M tropism to T tropism [5] [6] [7] , blocking the CCR5 coreceptor alone might favor the emergence of strains using CXCR4. It seems, therefore, that both coreceptors should be targeted by antiviral strategies aimed at blocking HIV-1 entry.
Stromal-cell-derived factor-1 (SDF-1) [8, 9] , a member of the Cys-X-Cys chemokine family, mediates an intracellular Ca 2+ rise and chemotaxis in CXCR4 + cells and is the only known ligand for CXCR4 [10, 11] . The 67 amino-acid form of SDF-1 (SDF-1α) was found to block infection by T-tropic HIV-1 [10, 11] , both by preventing a functional interaction between CXCR4 and gp120 and by inducing CXCR4 endocytosis [12] . In order to obtain leads for the design of small molecular weight compounds to block the HIV-1 coreceptor activity of CXCR4, we have screened peptides derived from SDF-1α for their antiviral activity. Furthermore, as antiviral compounds interfering with the CXCR4 signalling pathway might be detrimental in vivo, we have analyzed the signalling properties of SDF-1-derived antiviral peptides.
Results

Identification of a SDF-1-derived peptide retaining antiviral activity
The human SDF-1α sequence was synthesized as tridecapeptides that overlapped each other by 10 residues (pepscan) by microsynthesis on cellulose membranes [13, 14] . Peptides were screened in a rapid semi-quantitative assay based on the single-round infection of CD4 + HeLa P4.2 cells [15] by the HIV strain HIV-1 NDK [16] . This initial experiment revealed antiviral activity for peptides from the amino-terminal region of SDF-1, in particular the peptide KPVSLSYRCPCRF (in single-letter amino-acid code), corresponding to amino-acid residues 1-13 in SDF-1α (Figure 1a) . The optimal and minimal sizes required for antiviral activity were defined in a set of peptides obtained by progressive shortening of the sequence KPVSLSYRCPCRFFES, corresponding to residues 1-16 of SDF-1 (Figure 1b) . Four peptides had a higher antiviral activity than peptide 1-13. Two of them, including the most active peptide, VSLSYRCPCRFF (residues 3-14), had two phenylalanine residues (F13 and F14) at their carboxyl terminus. These residues were not present in the shortest antiviral peptide, LSYRCPCR (residues 5-12), however, and seemed dispensable for the 370 Current Biology, Vol 8 No 7
Figure 1
No peptide  900  KPVSLSYRCPCRF  16  SLSYRCPCRFFES  125  YRCPCRFFESHVA >800  PCRFFESHVARAN  >800  FFESHVARANVKH >800  SHVARANVKHLKI >800  ARANVKHLKILNT >800  NVKHLKILNTPNC >800  HLKILNTPNCALQ >800  ILNTPNCALQIVA >800  TPNCALQIVARLK >800  CALQIVARLKNNN >800  QIVARLKNNNRQV >800  ARLKNNNRQVCID >800  KNNNRQVCIDPKL >800  NRQVCIDPKLKWI >800  VCIDPKLKWIQEY >800  DPKLKWIQEYLEK >800  LKWIQEYLEKALN Inhibition of HIV-1 infection by SDF-1-derived peptides. HeLa P4.2 cells were infected in 96-well trays with HIV-1 NDK in the presence of the indicated peptides, and stained with X-Gal 24 h later. (a) Activity of 13-mer peptides spanning the whole sequence of mature human SDF-1α with an overlap of 10 residues between successive peptides. The number of infected cells (stained blue) per well in one experiment is shown. Peptides were synthesized on cellulose spots, and the whole amount was used for one well (maximal concentration 300 µM). Cys-Cys bridges are indicated by lines on the SDF-1α sequence. antiviral activity. The four amino-terminal residues of peptide 1-13 also seemed dispensable for antiviral activity. Dose-response experiments performed with selected peptides revealed 50% HIV-1 inhibitory concentrations (IC 50 ) in the range of 10-25 µM (Figure 1c) , confirming the conclusions drawn from the semi-quantitative pepscan experiments. The antiviral activities of the peptides determined with HIV-1 NDK extended to all other HIV-1 strains tested (HIV-1 LAI, HIV-1 NY5, HIV-1 GUN and HIV-1 89.6), with similar IC 50 values being obtained (data not shown). The slight antiviral effect of peptides representing the carboxyl terminus of SDF-1α observed in this experiment was not reproducible in dose-response experiments.
Identification of key residues for antiviral activity
In order to identify the key residues for the HIV-1 inhibitory activity in the sequence KPVSLSYRCPCRF (peptide 1-13), each residue was exchanged for all other amino acids, excluding cysteine. The ability of these peptides to block HIV-1 NDK infection was compared with that of the wild-type peptide (Figure 2a ). In accordance with our previous observations, the core sequence responsible for the antiviral activity appeared to start at the leucine residue L5. The core sequence is composed of two groups of residues that cannot be randomly exchanged for other amino acids without loss of antiviral activity. The first stretch, formed by residues LSY (at positions 5-7), and the second, formed by residues PCR (positions [10] [11] [12] , are separated by arginine and cysteine residues (R8 and C9) that are apparently less important for antiviral activity. Interestingly, the exchange of residue C9 for any aromatic amino acid resulted in peptides with higher antiviral activity. The relative importance of phenylalanine residue F13 was in agreement with previous observations (Figure 1b ). Dose-response experiments performed with selected peptides confirmed that certain amino-acid substitutions increased the antiviral activity of peptide 1-13 ( Figure 2b ). Moreover, both peptide 1-13 and one selected peptide analogue (KPVSHSYRCPCRF) were able to block HIV-1 NDK infection of U373CD4 + cells stably expressing CXCR4, but were not able to block
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Figure 2
Inhibition of HIV infection by analogues derived from an SDF-1 peptide. (a) Antiviral activity of 234 analogues derived from the KPVSLSYRCPCRF sequence (SDF-1 residues 1-13) by substituting each residue for other amino acids, as indicated (columns). All peptides were produced by microsynthesis on cellulose spots and tested in the same experiment, including the parental sequence as a control which was synthesised and tested 13 times (wt; upper row). For each analogue, the same fraction of the synthesis was added to the culture medium and HIV-1 infectivity tested as described in Figure 1 . This amount of parental peptide yielded an approximate 50% reduction of the infectious titres (that is, 600 infected cells per well, compared with 1200 infected cells per well for untreated cells). The antiviral activity of the analogues is represented by shading from black to white, as indicated. Darker shading corresponds to peptides with antiviral activity lower than the parental peptide, lighter shading corresponds to peptides blocking infection more efficiently than the parental peptide. One of two representative experiments is shown. Repeated pepscan with selected peptides gave similar results. 
Mechanism of antiviral activity
To clarify the mechanism by which the peptides inhibited HIV-1 entry, we analyzed their ability to induce CXCR4 internalization in the T-cell line CEM. After incubation at 37°C with peptides or with full-length SDF-1, cells were stained with the anti-CXCR4 monoclonal antibody 12G5 [17] and analyzed by flow cytometry. A dose-dependent downregulation of CXCR4 was observed upon treatment of cells with SDF-1, as expected; downregulation was also observed with peptide 1-13, but at markedly higher peptide concentrations (Table 1) . Peptides VSLSYR-CPCRFF (residues 3-14) and LSYRCPCRFF (residues 5-14) induced significant downregulation of CXCR4 expression only at 100 µM, whereas they both inhibited HIV-1 entry at lower concentrations (Figure 1c) . Overall, the ability of peptides to induce CXCR4 downregulation did not seem to correlate with their antiviral activity. In contrast, in direct competition assays, the binding of antibody 12G5 to CEM cells at 4°C was markedly reduced in the presence of peptide 1-13 and peptide 5-14 at concentrations within the range of their IC 50 values (Table 2) ; similar results were obtained with HeLa CCR5 + cells, in which the peptides competed with 12G5 for binding but not with an anti-CCR5 antibody (data not shown). Competition with 12G5 was more efficient for peptide 5-14, which has the lower IC 50 value (Figure 1c ). These experiments suggest that the antiviral activity of the SDF-1 peptides is mainly due to CXCR4 occupancy, rather than to the induction of CXCR4 endocytosis.
Signalling activities of different SDF-1 amino-terminal peptides
Given that antiviral peptides interact with CXCR4, they might interfere with its signalling activity. In CXCR4-expressing cells, such as HeLa cells, binding of SDF-1 results in an intracellular Ca 2+ rise [10] . This Ca 2+ rise was also observed after treatment of the cells with the antiviral peptide 1-13 at micromolar concentrations (Figure 3b ). Treatment with peptide 1-13 abolished the Ca 2+ response of cells to a subsequent stimulation by 50 nM SDF-1. Since the peptide was washed off the cells prior to SDF-1 addition, the lack of a Ca 2+ response was probably due to desensitization of CXCR4. Conversely, SDF-1 stimulation prior to peptide addition abrogated the peptide-induced signal (Figure 3a) , indicating that the peptide and chemokine bind to the same receptor, namely CXCR4. This peptide thus behaved as an agonist rather than an antagonist of CXCR4. Peptides lacking the amino-terminal lysine and proline residues (K1 and P2), in particular peptide 3-14, failed to induce a Ca 2+ response, indicating a key role for the K1 and P2 residues for signalling via CXCR4, although peptide 3-14 did appear to induce CXCR4 desensitization (Figure 3c ). An analogue of peptide 1-13, bearing a leucine to histidine substitution at position 5 (L5H), did not induce a Ca 2+ response in CXCR4 + cells (Figure 3d) , showing that the K1 and P2 residues are only part of a larger sequence required for signalling via CXCR4. Given that the peptide analogue L5H blocked HIV-1 entry more efficiently than any other peptide tested, its lack of signalling activity was unlikely to result from a lower affinity for CXCR4. Remarkably, treatment of cells with peptide analogue L5H did not significantly affect their response to subsequent stimulation by SDF-1 (Figure 3d ). In order to compare further the signalling activity of these peptides, we tested different concentrations of peptide 1-13 and peptide analogue L5H and recorded their signalling activity as well as their inhibitory effect on subsequent SDF-1 signalling in the continued presence of the peptide. These titrations revealed that peptide analogue L5H did not induce signalling at concentrations of 100 µM (Figure 4a ), and that its capacity to reduce subsequent SDF-1 stimulation was markedly reduced compared to the wild-type peptide 1-13 at concentrations of 50 µM (Figure 4b ; a reduction of the SDF-1 signal by 20-50% was observed for both peptides at doses even lower than 1 µM and might represent background inhibition rather than specific properties of the peptides). It should be recalled in this context that peptide analogue L5H blocked HIV infection with an IC 50 value of 4 µM (Figure 2b ). Peptide analogue L5H therefore appears to selectively block the HIV-1 coreceptor activity of CXCR4 without significantly interfering with its signalling function. This property was unique to the L5H analogue, because analogues C9W and P10W behaved in the same way as the parental 1-13 peptide (data not shown).
Discussion
We have shown that peptides derived from the amino terminus of the SDF-1 sequence retained both the ability to interact with the CXCR4 receptor and the antiviral activity of the chemokine. Antiviral peptides encompassing the entire amino-terminal sequence of SDF-1 induced signalling via CXCR4 followed by desensitization of the receptor. Peptides lacking the amino-terminal residues K1 and P2, or bearing the L5H mutation, failed to elicit a Ca 2+ response. These findings are compatible with a previous report, in which synthetic SDF-1 lacking the five amino-terminal amino-acid residues was devoid of antiviral activity and failed to elicit an intracellular Ca 2+ rise or chemotactic responses in CXCR4-expressing cells [18] . Peptides with deletions at their amino termini interfered with SDF-1 signalling despite being devoid of agonist activity. This result is in accordance with the recent description of full-length analogues of SDF-1, in which the exchange of K1 and P2 with other amino acids results in the generation of potent CXCR4 antagonists [19] . Most interestingly, we found that the single L5H mutation drastically reduced both the agonist activity of the peptide and the interference with SDF-1 signalling. This analogue had marked antiviral activity, however, that was superior to wild-type peptides.
The importance of the amino terminus of a chemokine for receptor recognition and cell activation is not without precedent. The sequence motif ELR, which precedes the Cys-X-Cys motif in the CXC chemokines that act on neutrophils, is essential for the binding and activation of both interleukin-8 receptors, CXCR1 and CXCR2 ( [20] and references therein). The corresponding region in SDF-1 consists of the LSY motif, which we found to be essential for HIV-1 inhibition. A two-site model derived from studies of the interaction of the complement fragment C5a with its receptor has been proposed for the interaction of chemokines with their receptors [21, 22] . In this model, an initial interaction takes place between the compact core of the chemokine and the amino terminus of the receptor (site I), followed by the interaction of the flexible amino terminus of the chemokine with site II, which is formed as a pocket by extracellular loops and membrane-spanning domains of the receptor. Interaction with site II leads to receptor activation. Recent studies with chimeric α-chemokines suggest that the amino terminus of SDF-1, which precedes the Cys-X-Cys motif and is apparently unstructured in solution, might engage a functional interaction with site II, whereas residues 12-17 (termed the RFFESH motif) are part of a structured loop and might contribute to receptor recognition [19] . Our data suggest that the SDF-1-derived peptides bind to site II, because they were able to mediate receptor activation. Antagonist peptides lacking the amino-terminal lysine and proline residues may interfere with SDF-1 signalling by inducing CXCR4 desensitization rather than by competing for receptor binding. Similar observations have been reported previously for non-agonist ligands of the nicotinic receptor [23] . The L5H peptide analogue, however, has strongly reduced signalling and desensitizing activities, because subsequent addition of SDF-1 resulted in signal transduction. The absence of the RFFESH motif in the small peptides might result in a failure to interact with site I, the site of initial receptor-chemokine interaction. Hence, the peptides could be relatively easily replaced by the amino-terminal moiety of SDF-1 after it has bound to the receptor via site I.
The ability of SDF-1-derived peptides to induce CXCR4 endocytosis correlated with their capacity to induce signal transduction, but did not correlate with their antiviral properties. This suggests that infection is blocked by mechanisms other than receptor endocytosis, possibly by direct competition with the HIV envelope protein gp120 for CXCR4 occupancy. This assumption is reinforced by the observation that SDF-1-derived peptides competed directly with the anti-CXCR4 monoclonal antibody 12G5.
It cannot be excluded, however, that the binding of peptides to CXCR4 induces an overall conformational change affecting the ability of CXCR4 to bind gp120 and 12G5 but not SDF-1. In the context of chimeric human/rat CXCR4, we found that the third extracellular domain (loop 2) of the human receptor was part of the 12G5 epitope [24] . Given that SDF-1-derived peptides compete for 12G5 binding and induce signalling, there seems to be a close relationship between the third extracellular domain of CXCR4 and site II. The 12G5 antibody blocks entry of a variety of HIV-1 strains; it seems plausible that peptides interfering with the 12G5 epitope might mask receptor determinants required for HIV entry via CXCR4. This assumption is in accordance with recent reports that other compounds blocking HIV-1 entry via CXCR4 also block 12G5 binding [25, 26] .
Our findings showing that the antiviral activity of SDF-1 is not indissociably linked with its CXCR4-mediated signalling activity via CXCR4 and that an SDF-1-derived peptide analogue can block HIV entry without markedly antagonizing SDF-1 have implications for future drug development. SDF-1-deficient mice have severe perturbations in the development of the B-cell and myeloid lineages and are not viable, suggesting an important function of the chemokine as a homing factor in bone marrow [27] . Moreover, SDF-1 might have additional functions, for example in T-cell homing and inflammatory processes, given that CXCR4 is expressed by a broad variety of cells [17] -a feature that seems unique amongst chemokine receptors. Although individuals with a homozygous CCR-5 deletion (∆CCR-5) show no apparent phenotype [28] , suggesting that CCR5 antagonists can be used in vivo, interference with the CXCR4-SDF-1 pathway might lead to severe side effects. Different inhibitors of HIV entry via CXCR4 have recently been described [25, 26, 29] ; all proved to be antagonists of SDF-1, however.
A recent report showed that a common polymorphism in the SDF-1 gene transcript correlated with the delayed onset of AIDS in HIV-infected individuals, suggesting that altered SDF-1 expression might prevent the emergence of virus strains using CXCR4 as a coreceptor and thus prevent rapid disease progression [30] . These data underline the importance of CXCR4 as an HIV-1 entry cofactor in vivo and thus reinforce the interest in the development of suitable agents to target this coreceptor.
Conclusions
Peptides derived from the amino terminus of SDF-1 retain both the ability to interact with CXCR4 and the antiviral property of the chemokine. These activities can be dissociated; removal of the amino-terminal residues K1 and P2 results in peptides that do not induce signalling via CXCR4 but that do desensitize the receptor. The L5H analogue of the peptide, encompassing the first 13 residues of SDF-1 and containing a leucine to histidine substitution, does not induce either significant signalling or desensitization of CXCR4, but does retain antiviral activity (IC 50 = 4 µM) superior to wild-type peptides. The antiviral activity is due to receptor occupancy rather than to receptor internalization. The identification of a non-agonistic, non-antagonistic antiviral peptide analogue opens new avenues for the future design of small molecular weight antiviral drugs that have selective inhibitory activities against HIV but do not interfere with CXCR4 signalling.
Materials and methods
Peptide synthesis
Peptide scans and substitution analogues were prepared by spot synthesis as described [13, 14] . After synthesis and cleavage of the protection groups, the peptides were released from the cellulose support as carboxamides by ammonia vapour. While still adsorbed to the membrane, the spots (0.25 cm 2 ) were punched out and transferred to wells of microtiter plates. Each spot contained roughly 30 nmol peptide. Larger amounts of selected peptides used in the dose-response experiments were prepared on a multiple peptide synthesizer (Abimed) according to the standard Fmoc machine protocols. These peptides were purified to greater than 95% and characterized by MALDI-TOF mass spectrometry. Peptides attached to cellulose discs were dissolved in water and added to cell culture at a final concentration of approximately 30 µM, except for the initial pepscan experiment (Figure 1a) , in which the whole quantity of peptide was dissolved in complete DMEM and used for one microtiter well. For dose-response experiments, peptide stock solutions (2 mM) were prepared in water and diluted into complete DMEM to the final concentration as indicated. Correspondence concerning peptides and peptide design should be addressed to J.S-M.
Infection assays
HIV-1 infectivity was scored using the CD4 + HeLa P4.2 cell line [15] , which is stably transfected with a lacZ reporter gene inducible by the viral protein Tat. HIV-infected cells can therefore be detected by virtue of their high level of β-galactosidase activity, yielding a blue staining in the presence of the 5-bromo-4-chloro-3-indoyl-D-galacto-pyranoside (X-Gal) substrate. Unless otherwise indicated, the HIV-1 NDK strain [16] (subtype D) was used for all infection assays. Viral stocks were supernatants of chronically infected CEM cells with infectious titers in the range of 10 5 -10 6 units/ml. For infections, HeLa P4.2 cells were seeded in 96-well trays (1 × 10 4 cells per 100 µl per well) in DMEM with 10% fetal calf serum and allowed to adhere overnight. The supernatant was replaced by an equivalent volume of medium containing virus (1-4 × 10 3 infectious units per well as indicated) and peptide as indicated. Cells were fixed in 0.5% glutaraldehyde 24 h later, and stained with X-Gal, as described [31] . Blue-stained cells were scored under 20× magnification. Control experiments were performed using the astroglioma cell line U373CD4 + LTRlacZ stably expressing either CXCR4, or CCR5 bearing a Myc tag at its amino terminus, using the same procedure. The CCR5 + clone was infected with the HIV-1 YU2 isolate produced by HeLa cells transfected with proviral DNA.
CXCR4 downregulation
Surface expression of CXCR4 in CEM cells was analyzed as described [12] . Briefly, cells (5 × 10 5 ) were incubated for 40 min at 37°C with either SDF-1, peptides, or medium alone. The cells were then washed with an acidic glycine buffer, incubated at 4°C with 12G5 monoclonal antibody and subsequently labelled with a phycoerythrin (PE)-conjugated secondary antibody (Southern Biotechnology). After staining, cells were fixed in 1% paraformaldehyde and CXCR4 expression was analyzed with a FACScan cytofluorometer (Becton Dickinson).
Competition of peptides with 12G5
To detect competition for CXCR4 binding, peptides or SDF-1, together with 12G5 antibody (6 µg/ml) were added simultaneously to 1 × 10 6 CEM cells. After 45 min on ice, cells were washed, stained with a PEconjugated secondary antibody (DAKO) and analyzed by flow cytometry as described [24] . Control experiments were performed on HeLa CCR5 + cells using either 12G5 or 2D7 (anti-CCR5, obtained from the NIH AIDS Reagent Program) antibodies.
Intracellular calcium measurements
HeLa cells were loaded with the fluorescent dye fura-2 (3 µM) in mammalian saline buffer (140 mM NaCl, 5 mM KCl, 10 mM HEPES pH 7.4, 1 mM CaCl 2 , 1 mM MgCl 2 ) for 30 min at room temperature. The same buffer was used to wash the cells before the addition of SDF-1 or peptides at the indicated concentrations. Single-cell Ca 2+ measurements were made at 37°C with a Nikon Diaphot 300 microscope and an IMSTAR imaging system (Paris) as described [32] . Fura-2 fluorescence was excited alternatively at 380 nm and 350 nm. Four images were averaged at each wavelength and one Ca 2+ image was generated every 6 sec.
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